Why cost and treatment length are some of the biggest concerns for drug manufacturers.
Managed Healthcare Executive’s Managed Care Pharmacy Survey identifies different ways specialty pharmacy stakeholders believe they can reduce industry costs moving forward.
The real-world strategies used to manage the high cost of specialty meds.
Specialty pharmaceuticals make up a huge part of the current drug market, and their impact is only going to grow over the next few years.
How would you define a specialty pharmaceutical? Chances are, it’s different from the way another healthcare executive would define them.
Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?